IPP Bureau
Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US
By IPP Bureau - August 31, 2022
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia
By IPP Bureau - August 31, 2022
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Merck to present new data of oncology portfolio at ESMO 2022
By IPP Bureau - August 30, 2022
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
Thermo Fisher Scientific present new innovations to improve biopharmaceutical and proteomics workflows
By IPP Bureau - August 30, 2022
New mass spectrometry instrument and consumables launch during IMSC 2022
KIMS Hospitals to acquire majority stake in Kingsway Hospitals, Nagpur
By IPP Bureau - August 30, 2022
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
Dr. Mansukh Mandaviya and Bhagwanth Khuba to grace Silver Jubilee function of NPPA
By IPP Bureau - August 29, 2022
To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched
Ayush Minister unveils “Science Behind Suryanamaskar” book
By IPP Bureau - August 29, 2022
The book “Science behind Suryanamaskar” has been compiled by the AIIA’s Department of Swasthavritta and Yoga.
Lupin receives tentative approval from USFDA for Dasatinib Tablets
By IPP Bureau - August 29, 2022
Dasatinib Tablets (RLD Sprycel) had estimated annual sales of USD 1569 million in the U.S. (IQVIA MAT June 2022).
Eiko Lifesciences enters into MOU with Delicare Lifesciences
By IPP Bureau - August 29, 2022
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
Alembic Pharmaceuticals completes USFDA RRA for its bioequivalence facility
By IPP Bureau - August 29, 2022
The RRA was conducted from 22nd August, 2022 to 26th August, 2022.
USFDA completes inspection at Aurolife Pharma’s Raleigh unit
By IPP Bureau - August 29, 2022
The unit has filed 2 Derma products and 1 MDI product.
Alembic Pharmaceuticals receives USFDA final approval for Chlorthalidone Tablets USP
By IPP Bureau - August 29, 2022
he approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Hygroton Tablets, 25 mg and 50 mg, of Sanofi Aventis US. LLC (Sanofi).
SciGenom announces Phd program in collaboration with CHARUSAT University
By IPP Bureau - August 29, 2022
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
Moderna sues Pfizer, BioNTech for mRNA patent infringement
By IPP Bureau - August 28, 2022
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Qdenga approved in Indonesia for use regardless of prior dengue exposure
By IPP Bureau - August 28, 2022
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
